Trial document



drksid header

  DRKS00016923

Trial Description

start of 1:1-Block title

Title

Surgery for adenocarcinoma of the gastroesophageal junction (GEJ) type II:
Transthoracic esophagectomy vs. transhiatal extended gastrectomy.

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

CARDIA Trial

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

The CARDIA study examines malignant tumors located directly at the transition between the esophagus and stomach. By surgically removing the tumour, this cancer can be cured in some of the affected patients. There are currently two possible surgical procedures.
One procedure is the transthoracic oesophagectomy with stomach elevation. During this procedure, a large part of the oesophagus is removed together with the oesophageal-gastric-transition. The stomach is then formed into a tube and connected to the rest of the esophagus in the chest cavity.
The other operation is the transhiatal extended gastrectomy. In this procedure, the stomach is removed together with the oesophageal-gastric-transition. A connection is then created between the esophagus and a part of the small intestine.
Both procedures allow complete removal of the tumor. However, they are associated with different risks and complications. So far, it has not been possible to determine scientifically which of the two operations is better suited for the treatment of transitional tumors. The aim of this clinical study is therefore to compare the two procedures in terms of healing rates and the resulting quality of life.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

Adenocarcinomas of the gastroesophageal Junction (GEJ) type II can be resected either by transthoracic oesophageectomy or transhiatal extended gastrectomy. Both surgical procedures allow a complete tumor resection. To date, it has not been determined which surgery is superior in terms of quality of life, oncological outcome and survival, as only retrospective studies with contradictory results have been conducted so far. The CARDIA trial compares both surgical procedures in a non-blinded, multinational, multicenter, prospectively randomized study design. Patients with an GEJ type II tumor that can be resected by both transthoracic esophagectomy and transhiatal gastrectomy will be enrolled in the trial and will be operated after randomization using one of the investigated surgical procedure. Primary endpoint is overall survival. Secondary endpoints are complete resection (R0), number and location of tumor-infiltrated lymph nodes, postoperative complications, disease-free survival, quality of life and cost-effectiveness. Postoperative survival, disease-free survival and quality of life are monitored for 24 months after discharge. Overall survival is then monitored through quarterly telephone calls up to 60 months after surgery.

end of 1:1-Block scientific synopsis
start of 1:1-Block forwarded Data

Do you plan to share individual participant data with other researchers?

No

end of 1:1-Block forwarded Data
start of 1:1-Block forwarded Data Content

Description IPD sharing plan:

[---]*

end of 1:1-Block forwarded Data Content
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00016923
  •   2019/08/02
  •   [---]*
  •   yes
  •   Approved
  •   19-1376, Ethik-Kommission der Medizinischen Fakultät der Universität zu Köln
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  • [---]*
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   C16.0 -  Malignant neoplasm: Cardia
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Transthoracic esophagectomy (removal of the esophagus and intrathoracic connection of the esophagus to the stomach)
  •   Transhiatal extended gastrectomy (Removal of the stomach and the lower part of the esophagus with esophageal jejunostomy)
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Open (masking not used)
  •   [---]*
  •   Active control (effective treament of control group)
  •   Treatment
  •   Parallel
  •   IV
  •   N/A
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Overall survival (Follow-up up to 60 months after discharge)

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

Complete (R0) resection, post-operative complications according to the Dindo-Clavien classification, number and Tumor Infiltration of lymph nodes at dissection, quality of life (EORTC QLQ-C30, -STO22, -OG25 after 3, 6, 12, 18, 24 months), cost-effectiveness

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
  •   Netherlands
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • University Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Actual
  •   2020/04/16
  •   262
  •   Multicenter trial
  •   International
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

• Histologically proven adenocarcinoma of the GEJ type II
• Non-metastatic tumor, resectable by both transthoracic esophagectomy and transhiatal extended gastrectomy according to the local surgical investigator
• Age ≥ 18
• ECOG Eastern Cooperative Oncology Group (ECOG) performance status 0–2
• ASA < 4.
• Pre-treatment stage cT1-4a N0/N+, M0
• In case of stage cT4a, curative resectability must be explicitly verified by the local surgical investigator prior to randomization
• Patients with locally advanced tumors (T3-T4 or N+) who received four cycles of chemotherapy (FLOT) preoperatively
• Negative serum pregnancy test during screening period for women of child-bearing age
• Patients with a cardiac history should receive a cardiology consultation and should have a left ventricular ejection fraction > 50% (determined by echocardiography)
• Adequate respiratory function (pulmonary function tests only necessary in symptomatic patients) with FEV1>/= 1.5 l/s
• Adequate bone marrow function (white blood cells > 3x10^9 /l; hemoglobin > 9 g/dl; platelets > 100x10^9 /l), renal function (glomerular filtration rate >60 ml/min), and liver function (total bilirubin < 1.5x upper level of normal (ULN), aspartate transaminase (AST) < 2.5x ULN and alanine transaminase (ALT) < 3x ULN)
• Written informed consent

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

• Tumors of squamous, adenosquamous or another non-adenocarcinoma histology
• Advanced inoperable or metastatic GEJ type II adenocarcinoma
• GEJ type II adenocarcinoma staged cT4b, M+
• GEJ type II cT4a evaluated as not curatively resectable by the local surgical investigator
• Histologically proven adenocarcinoma of the GEJ type I and III
• Severe tumor stenosis preventing endoscopic tumor classification
• Tumor expanding more than 5 cm proximal of the GEJ
• Tumor resectable only by transthoracic esophagectomy or only by transhiatal extended gastrectomy, according to the local surgical investigator
• Positive lymph nodes only resectable by transthoracic esophagectomy (i.e. in the mid-upper mediastinum) or only resectable by transhiatal extended gastrectomy according to the local surgical investigator.
• Patients with locally advanced tumors (T3-T4 or N+) who did not receive chemotherapy (FLOT) preoperatively or received more or less than the allowed 4 cycles of chemotherapy
• Clinically significant (active) cardiac disease (e.g. symptomatic coronary artery disease or myocardial infarction within last 12 months)
• Clinically significant lung disease (forced expiratory volume in one second (FEV1) < 1.5 l/s)
• Pregnant women and nursing mothers
• Persons with any kind of dependency on the principal investigator or employed by the sponsor or principal investigator
• Legally incapacitated persons
• Persons held in an institution by legal or official order

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Universitätsklinik Köln Klinik und Poliklinik für Allgemein- Viszeral- und Tumorchirurgie
    • Ms.  Prof. Dr.  Christiane  Bruns 
    • Kerpener Str. 62
    • 50937  Köln
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Universitätsklinik Köln Klinik und Poliklinik für Allgemein- Viszeral- und Tumorchirurgie
    • Ms.  Prof. Dr.  Christiane  Bruns 
    • Kerpener Str. 62
    • 50937  Köln
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Universitätsklinik Köln Klinik und Poliklinik für Allgemein- Viszeral- und Tumorchirurgie
    • Ms.  Prof. Dr.  Christiane  Bruns 
    • Kerpener Str. 62
    • 50937  Köln
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bundesministerium für Bildung und Forschung Dienstsitz Berlin
    • Friedrichstraße 130 B
    • 10117  Berlin
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.